InsiderTrades.com logo
Mark Corrigan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mark Corrigan Biography and Net Worth

Director of WAVE Life Sciences

Dr. Corrigan currently serves as a member of the board of directors of Silver Creek Pharmaceuticals, Inc. and AstronauTX, both privately held biotechnology companies. Dr. Corrigan also serves as a Strategic Advisor to Ceretype Neuromedicine. Dr. Corrigan previously served as the Chief Executive Officer of Correvio Pharma Corp. from March 2019 to May 2020, and served as President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co-founder) from 2016 to March 2019. Prior to the founding of Tremeau, he held several executive positions at Zalicus, Inc., Sepracor and Pharmacia Corp. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Throughout his career, he personally led discovery and development efforts of multiple novel therapeutic approaches and has raised substantial capital through public markets to fund research, development and company operations. Dr. Corrigan is board certified in psychiatry and neurology and began his career as an Adjunct Professor in the Department of Psychiatry at the University of North Carolina. Dr. Corrigan holds a BA and a medical degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.

What is Mark Corrigan's net worth?

The estimated net worth of Mark Corrigan is at least $372.87 thousand as of December 8th, 2025. Corrigan owns 28,815 shares of WAVE Life Sciences stock worth more than $372,866 as of January 31st. This net worth approximation does not reflect any other investments that Corrigan may own. Learn More about Mark Corrigan's net worth.

How do I contact Mark Corrigan?

The corporate mailing address for Corrigan and other WAVE Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. WAVE Life Sciences can also be reached via phone at (656) 236-3388 and via email at [email protected]. Learn More on Mark Corrigan's contact information.

Has Mark Corrigan been buying or selling shares of WAVE Life Sciences?

Mark Corrigan has not been actively trading shares of WAVE Life Sciences during the past quarter. Most recently, Mark Corrigan sold 16,115 shares of the business's stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.48, for a transaction totalling $217,230.20. Following the completion of the sale, the director now directly owns 28,815 shares of the company's stock, valued at $388,426.20. Learn More on Mark Corrigan's trading history.

Who are WAVE Life Sciences' active insiders?

WAVE Life Sciences' insider roster includes Paul Bolno (CEO), Mark Corrigan (Director), Chris Francis (insider), Christian Henry (Director), Kyle Moran (CFO), Adrian Rawcliffe (Director), Ken Takanashi (Director), Gregory Verdine (Director), and Heidi Wagner (Director). Learn More on WAVE Life Sciences' active insiders.

Are insiders buying or selling shares of WAVE Life Sciences?

In the last twelve months, WAVE Life Sciences insiders bought shares 1 times. They purchased a total of 1,470,000 shares worth more than $27,930,000.00. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 1,363,535 shares worth more than $17,815,766.35. The most recent insider tranaction occured on January, 2nd when insider Chris Francis sold 9,375 shares worth more than $150,281.25. Insiders at WAVE Life Sciences own 24.0% of the company. Learn More about insider trades at WAVE Life Sciences.

Information on this page was last updated on 1/2/2026.

Mark Corrigan Insider Trading History at WAVE Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2025Sell16,115$13.48$217,230.2028,815View SEC Filing Icon  
See Full Table

Mark Corrigan Buying and Selling Activity at WAVE Life Sciences

This chart shows Mark Corrigan's buying and selling at WAVE Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

WAVE Life Sciences Company Overview

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $12.94
Low: $12.75
High: $13.21

50 Day Range

MA: $14.03
Low: $6.99
High: $21.31

2 Week Range

Now: $12.94
Low: $5.28
High: $21.73

Volume

2,326,426 shs

Average Volume

4,587,866 shs

Market Capitalization

$2.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A